100% tevredenheidsgarantie Direct beschikbaar na betaling Zowel online als in PDF Je zit nergens aan vast
logo-home
Samenvatting - BMS72 - Cancer development and immune defense (BMS72) Summary €7,99
In winkelwagen

Samenvatting

Samenvatting - BMS72 - Cancer development and immune defense (BMS72) Summary

 8 keer bekeken  0 keer verkocht

Deze samenvatting bevat alle onderwerpen behandeld tijdens het master vak BMS72 - Cancer development and immune defense (stem cell biology, hematopoiesis, leukemia, ChIP, AML/MDS, clonal evolution, epigentics, histone acetylation/methylation, DNA methylation, epigenetics in cancer, NK cells, T cell...

[Meer zien]

Voorbeeld 4 van de 19  pagina's

  • 27 november 2024
  • 19
  • 2024/2025
  • Samenvatting
Alle documenten voor dit vak (3)
avatar-seller
StudentRU07
BMS72 – Cancer Development and Immune Defense




BMS72 – CANCER DEVELOPMENT
AND IMMUNE DEFENSE




Opleiding: Master Biomedical Sciences
Onderwijsinstelling: Radboudumc




1

, BMS72 – Cancer Development and Immune Defense




Content
Stem cell biology...............................................................................................................................4
Normal hematopoiesis..........................................................................................................................................4
Development of leukemia.....................................................................................................................................4
Targeted therapy...................................................................................................................................................5

Clonal evolution in myeloid malignancies..........................................................................................5
Mutations and hematopoiesis..............................................................................................................................5
Clonal hematopoiesis of indeterminate potential (ChIP).....................................................................................6
Biomarkers in AML/MDS.......................................................................................................................................6
Clonal evolution in MDS/AML...............................................................................................................................7

Epigenetics........................................................................................................................................7
What is epigenetics?.............................................................................................................................................7
How is gene expression regulated?.......................................................................................................................7
Histone acetylation..........................................................................................................................................7

Histone methylation........................................................................................................................................8

DNA methylation.............................................................................................................................................8

Binding PRC1...................................................................................................................................................8

Epigenetics and cancer..........................................................................................................................................8
Histone methylation – EZH2............................................................................................................................8

DNA methylation – DNMT3a and TET2...........................................................................................................9

Refreshment immunology...............................................................................................................10
NK cells................................................................................................................................................................10
Dendritic cells......................................................................................................................................................10
T cells...................................................................................................................................................................11

Immune therapy..............................................................................................................................12
Allogeneic stem cell transplantation...................................................................................................................12
CAR T cell therapy...............................................................................................................................................13

Modulation of the tumor microenvironment..................................................................................14
The cancer-immunity cycle.................................................................................................................................14
Cancer immunoediting........................................................................................................................................14
The cancer immunogram....................................................................................................................................16

Dendritic cell-based vaccines...........................................................................................................17

2

, BMS72 – Cancer Development and Immune Defense



Production...........................................................................................................................................................17
Quality control.....................................................................................................................................................18




3

, BMS72 – Cancer Development and Immune Defense


Stem cell biology
Normal hematopoiesis
Hematopoietic stem cells (HSCs) are a type of stem cell responsible for forming blood cells. These cells remain
mostly in a “quiescent” or inactive state, dividing only about once every 25 to 50 weeks. This slow division rate
is key to preserving them throughout a person’s life, helping protect them from mutations that could arise from
frequent cell division. Because of this low division frequency, HSCs can function and remain viable over an
individual's entire lifetime.

Cells express unique combinations of molecules on their membrane and in
their cytoplasm (e.g. adhesion molecules, growth factor receptors,
transcription factors, effector molecules in granules, etc). The expression of
these molecules can be studied using fluorochrome-labeled (monoclonal)
antibodies, which can be detected by flow cytometry.

During their maturation, hematopoietic cells express proteins on their cell
membrane (so-called CD markers) and the composition of these proteins
depends on the developmental stage the cell is in. Hematopoietic stem cells
express the surface molecule CD34 on their cell membrane and are CD38 -.
Progenitor cells are CD34+CD38+ and matured blood cells are CD34-CD38+. The combination of the following
markers is typically used to identify HSC populations: CD34+, CD38-, Thy-1+, c-kit+, IL-3R-.
↪ “The” stem cell cannot be identified just by cell surface markers; we can only identify populations.

Development of leukemia
Leukemia is a cancer caused by genetic mutations that disrupt the balance of
cell proliferation, differentiation, and apoptosis. It results in more than 20%
immature cells, or blasts, in the bone marrow. Leukemia types are broadly
categorized as myeloid or lymphoid and as acute (rapid progression) or chronic
(slower progression). Initially, leukemia subtypes were classified based on cell
morphology, but nowadays genetic classification is included.

Leukemia treatment aims for a cure, typically starting with two rounds of
intensive chemotherapy, followed by a third round in some cases, depending
on patient fitness. The only curative treatment for leukemia is
autologous/allogeneic transplantation.

Leukemia develops through the sequential accumulation of mutations resulting in the
formation of leukemia initiating stem cells. These cells differentiate towards progenitor cells that proliferate
growth factor independent and that are blocked in their differentiation (differentiation block). Leukemia is a
multistep process in which more than 1 error must arise in the cell's genetic material. Genes that are mutated
in leukemia can be classified in four major biological groups:
 Growth factor receptors
 Signal transduction molecules
 Gene expression regulation (transcription factors, epigenetic regulators, RNA splicing factors or
chromatin organization)
 Apoptosis
↪ For full blown leukemia development usually a combination of mutations in 2-3 genes from different
categories is necessary.

Normal stem cell: generation of all mature blood cell types, life long.
Cancer stem cell: continuous generation of more differentiated immature leukemia blasts.

Leukemia likely originates from an early stem cell. When immature blast cells are transplanted into mice, they
seldom lead to leukemia. In contrast, early leukemia stem cells (LSCs) frequently cause leukemia upon
transplantation, indicating that LSCs are more likely to initiate the disease. However, it does not imply that the
cancer stem cell is directly derived from a normal stem cell, it can also be derived from a more mature cell.
4

Voordelen van het kopen van samenvattingen bij Stuvia op een rij:

Verzekerd van kwaliteit door reviews

Verzekerd van kwaliteit door reviews

Stuvia-klanten hebben meer dan 700.000 samenvattingen beoordeeld. Zo weet je zeker dat je de beste documenten koopt!

Snel en makkelijk kopen

Snel en makkelijk kopen

Je betaalt supersnel en eenmalig met iDeal, creditcard of Stuvia-tegoed voor de samenvatting. Zonder lidmaatschap.

Focus op de essentie

Focus op de essentie

Samenvattingen worden geschreven voor en door anderen. Daarom zijn de samenvattingen altijd betrouwbaar en actueel. Zo kom je snel tot de kern!

Veelgestelde vragen

Wat krijg ik als ik dit document koop?

Je krijgt een PDF, die direct beschikbaar is na je aankoop. Het gekochte document is altijd, overal en oneindig toegankelijk via je profiel.

Tevredenheidsgarantie: hoe werkt dat?

Onze tevredenheidsgarantie zorgt ervoor dat je altijd een studiedocument vindt dat goed bij je past. Je vult een formulier in en onze klantenservice regelt de rest.

Van wie koop ik deze samenvatting?

Stuvia is een marktplaats, je koop dit document dus niet van ons, maar van verkoper StudentRU07. Stuvia faciliteert de betaling aan de verkoper.

Zit ik meteen vast aan een abonnement?

Nee, je koopt alleen deze samenvatting voor €7,99. Je zit daarna nergens aan vast.

Is Stuvia te vertrouwen?

4,6 sterren op Google & Trustpilot (+1000 reviews)

Afgelopen 30 dagen zijn er 52510 samenvattingen verkocht

Opgericht in 2010, al 14 jaar dé plek om samenvattingen te kopen

Start met verkopen
€7,99
  • (0)
In winkelwagen
Toegevoegd